RU2002115864A - Лечение злокачественных опухолей аплидином - Google Patents

Лечение злокачественных опухолей аплидином

Info

Publication number
RU2002115864A
RU2002115864A RU2002115864/14A RU2002115864A RU2002115864A RU 2002115864 A RU2002115864 A RU 2002115864A RU 2002115864/14 A RU2002115864/14 A RU 2002115864/14A RU 2002115864 A RU2002115864 A RU 2002115864A RU 2002115864 A RU2002115864 A RU 2002115864A
Authority
RU
Russia
Prior art keywords
aplidine
weeks
week
dose
malignant tumors
Prior art date
Application number
RU2002115864/14A
Other languages
English (en)
Other versions
RU2261104C2 (ru
Inventor
Глинн Томас ФЭЙРКЛОТ (US)
Глинн Томас ФЭЙРКЛОТ
Крис ТВЕЛВЗ (GB)
Крис ТВЕЛВЗ
Луис ПАС-АРЕС (ES)
Луис ПАС-АРЕС
Original Assignee
Фарма Мар С.А. (Es)
Фарма Мар С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Фарма Мар С.А. (Es), Фарма Мар С.А. filed Critical Фарма Мар С.А. (Es)
Publication of RU2002115864A publication Critical patent/RU2002115864A/ru
Application granted granted Critical
Publication of RU2261104C2 publication Critical patent/RU2261104C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (6)

1. Эффективный способ лечения злокачественных опухолей у пациента, предусматривающий введение аплидина в дозе, не превышающей рекомендуемую дозу, в соответствии с данными по ограничивающей дозу токсичности.
2. Способ по п.1, где введение дозы выполняют в соответствии с одной из следующих процедур: 24-часовая инфузия один раз в неделю в течение трех недель, с последующей одной неделей отдыха; 24-часовая инфузия один раз в две недели; 1-часовая инфузия один раз в неделю в течение 3 недель через каждые 4 недели; инфузия один раз в день, например, 1 час × 5 дней через каждые 3 недели; и 3-часовая инфузия каждую вторую неделю.
3. Способ по п.1, где аплидин ингибирует секрецию VEGF и аутокринную петлю VEGF/VEGF.
4. Способ по п.1, где аплидин вводят в виде части комбинированной терапии.
5. Способ по п.1, где аплидин вводят в сочетании с защитным агентом скелетных мышц.
6. Способ по п.1, где пациент уже получал ранее стандартное лечение злокачественных опухолей, и опухоль является резистентной.
RU2002115864/14A 1999-11-15 2000-11-15 Лечение злокачественных опухолей аплидином RU2261104C2 (ru)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB9927006.8 1999-11-15
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0005701.8 2000-03-09
GB0007639.8 2000-03-29
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0015496.3 2000-06-23
GB0025209.8 2000-10-13
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers

Publications (2)

Publication Number Publication Date
RU2002115864A true RU2002115864A (ru) 2004-01-20
RU2261104C2 RU2261104C2 (ru) 2005-09-27

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002115864/14A RU2261104C2 (ru) 1999-11-15 2000-11-15 Лечение злокачественных опухолей аплидином

Country Status (27)

Country Link
US (1) US20090298752A1 (ru)
EP (1) EP1229922B1 (ru)
JP (1) JP2003514025A (ru)
KR (1) KR100518986B1 (ru)
CN (1) CN1423564A (ru)
AT (1) ATE363910T1 (ru)
AU (1) AU780417B2 (ru)
BG (1) BG65381B1 (ru)
BR (1) BR0015811A (ru)
CA (1) CA2391502A1 (ru)
CY (1) CY1106825T1 (ru)
CZ (1) CZ302498B6 (ru)
DE (1) DE60035120T2 (ru)
DK (1) DK1229922T3 (ru)
ES (1) ES2288486T3 (ru)
HK (1) HK1045648B (ru)
HU (1) HUP0203906A2 (ru)
IL (1) IL149488A0 (ru)
MX (1) MXPA02004862A (ru)
NO (1) NO330719B1 (ru)
NZ (1) NZ518847A (ru)
PL (1) PL200922B1 (ru)
PT (1) PT1229922E (ru)
RU (1) RU2261104C2 (ru)
SI (1) SI1229922T1 (ru)
SK (1) SK287762B6 (ru)
WO (1) WO2001035974A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (ru) 2000-06-30 2006-09-15 Фарма Мар, С.А. Противоопухолевые производные аплидина
ES2243555T3 (es) 2000-10-12 2005-12-01 Pharma Mar, S.A. Tratamiento de canceres mediante aplidina en conjuncion con carnitina o acetilcarnitina.
AU2002336206B2 (en) * 2001-10-19 2007-11-29 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
MXPA05009741A (es) * 2003-03-12 2005-11-16 Pharma Mar Sa Tratamientos antitumorales mejorados.
NZ571043A (en) * 2006-02-28 2012-06-29 Pharma Mar Sa Anticancer combination of aplidine and dexamethasone
BRPI0717998A2 (pt) * 2006-11-03 2013-12-03 Nerviano Medical Sciences Srl Método para administrar um composto antitumor.
EP2205263A1 (en) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
MX2010009697A (es) * 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0048149B1 (en) * 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
EP0220453B1 (de) * 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
CA2288639A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE60123232T2 (de) * 2000-04-07 2007-11-08 Trustees Of The University Of Pennsylvania Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (ru) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Противоопухолевые производные аплидина
EP1325032A2 (en) * 2000-10-05 2003-07-09 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
ES2243555T3 (es) * 2000-10-12 2005-12-01 Pharma Mar, S.A. Tratamiento de canceres mediante aplidina en conjuncion con carnitina o acetilcarnitina.
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
AU2002336206B2 (en) * 2001-10-19 2007-11-29 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
MXPA05009741A (es) * 2003-03-12 2005-11-16 Pharma Mar Sa Tratamientos antitumorales mejorados.
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
WO2004084812A2 (en) * 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
NZ571043A (en) * 2006-02-28 2012-06-29 Pharma Mar Sa Anticancer combination of aplidine and dexamethasone
EP2205263A1 (en) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
PL355335A1 (en) 2004-04-19
ATE363910T1 (de) 2007-06-15
SK287762B6 (sk) 2011-09-05
AU1402301A (en) 2001-05-30
JP2003514025A (ja) 2003-04-15
CY1106825T1 (el) 2012-05-23
DE60035120D1 (de) 2007-07-19
SI1229922T1 (sl) 2008-04-30
BG65381B1 (bg) 2008-05-30
CZ302498B6 (cs) 2011-06-15
IL149488A0 (en) 2002-11-10
DE60035120T2 (de) 2008-01-31
HK1045648A1 (en) 2002-12-06
CA2391502A1 (en) 2001-05-25
PL200922B1 (pl) 2009-02-27
PT1229922E (pt) 2007-09-12
MXPA02004862A (es) 2003-01-28
WO2001035974A3 (en) 2001-11-01
NO20022293D0 (no) 2002-05-14
DK1229922T3 (da) 2007-10-08
EP1229922A2 (en) 2002-08-14
US20090298752A1 (en) 2009-12-03
NZ518847A (en) 2004-02-27
NO20022293L (no) 2002-07-05
RU2261104C2 (ru) 2005-09-27
WO2001035974A2 (en) 2001-05-25
KR100518986B1 (ko) 2005-10-06
NO330719B1 (no) 2011-06-20
BR0015811A (pt) 2002-08-06
CZ20021697A3 (cs) 2003-02-12
HUP0203906A2 (en) 2003-03-28
SK6592002A3 (en) 2003-08-05
KR20020064313A (ko) 2002-08-07
ES2288486T3 (es) 2008-01-16
CN1423564A (zh) 2003-06-11
AU780417B2 (en) 2005-03-17
HK1045648B (zh) 2007-09-21
EP1229922B1 (en) 2007-06-06
BG106714A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
RU2002115864A (ru) Лечение злокачественных опухолей аплидином
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
JP2015163628A (ja) 腫瘍転移および癌の治療
ATE383168T1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
ATE458500T1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CA2265547A1 (en) Method of treating endothelial injury
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
Etcubanas et al. Adjuvant chemotherapy for osteogenic sarcoma
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
Link et al. Cutaneous manifestations of taxol® therapy
Dalley Radiotherapy and chemotherapy in treatment of head and neck cancer
Straus New developments in the treatment of advanced lung cancer
Stephens The place of chemotherapy in the treatment of advanced squamous carcinoma of the head and neck and in other situations
RU2048824C1 (ru) Способ лечения злокачественных опухолей
Marshall et al. Metastatic seminoma of testis treated by oral nitrofurazone (Furacin) and radiotherapy
Hyman et al. Combination therapy of malignant hemangioendothelioma with radiation and methotrexate
v Scheel et al. A special method of intra-arterial infusion for treatment of head and neck cancer
RU2000124536A (ru) Применение эпотилонов для лечения рака
RU2001133467A (ru) Композиции и применение ЕТ743 для лечения злокачественных опухолей
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
Slavik et al. Phase II studies in advanced, recurrent pelvic malignancies conducted by the gynecologic oncology group (GOG): Experimental design and experience
Favalli Biological response modifiers for the therapy of cancer and infectious diseases

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111116